Tuborg Havnevej 15, st.
Ground Floor
Hellerup 2900
Denmark
45 45 29 00 00
https://bioporto.com
Sector(s): Healthcare
Industry: Diagnostics & Research
Full Time Employees: 27
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Peter Moerch Eriksen B.B.A., BBA | Chief Executive Officer | 42.03k | N/A | 1960 |
Prof. Lars Otto Uttenthal | Chief Scientific Officer | N/A | N/A | N/A |
Ms. Gry Husby Larsen | Executive VP & Chief Legal Officer | N/A | N/A | N/A |
Ms. Jennifer Zonderman | SVP of Global Marketing & US Commercialization | N/A | N/A | N/A |
Mr. Nis Kruse | Executive VP of Strategic Partnerships and GM of EMEA & APAC | N/A | N/A | N/A |
Mr. Jeffrey N. Haas | President & CEO of BioPorto Inc. | N/A | N/A | N/A |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S’s ISS Governance QualityScore as of June 1, 2024 is 3. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 1; Compensation: 8.